Citations (51)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Xiaoyun Hu, Wenyan Qin, Shanqiong Li, Miao He, Yilin Wang, Shu Guan, Haishan Zhao, Weifan Yao, Minjie Wei, Mingyan Liu & Huizhe Wu. (2019) Polymorphisms in DNA repair pathway genes and ABCG2 gene in advanced colorectal cancer: correlation with tumor characteristics and clinical outcome in oxaliplatin-based chemotherapy. Cancer Management and Research 11, pages 285-297.
Read now
Read now
Yan Liu, Zhong Zheng, Qixin Zhang, Xinling Zhou, Yikuan Feng & Anquan Yan. (2017) FOLFOX regimen plus dendritic cells–cytokine-induced killer cells immunotherapy for the treatment of colorectal cancer: a meta-analysis. OncoTargets and Therapy 10, pages 2621-2633.
Read now
Read now
Articles from other publishers (49)
Yasir G. Malik, Jūratė Šaltytė Benth, Hanne M. Hamre, Arne E. Færden, Dejan Ignjatovic & Johannes K. Schultz. (2023)
Chemotherapy reduces long‐term quality of life in recurrence‐free colon cancer survivors (
LaTE
study)—a nationwide inverse probability of treatment‐weighted registry‐based cohort study and survey
. Colorectal Disease.
Crossref
Crossref
Ruben A G van Eerden, Nadine L de Boer, Job P van Kooten, Checca Bakkers, Michelle V Dietz, Geert-Jan M Creemers, Sanne M Buijs, Ramon Bax, Femke M de Man, Robin J Lurvink, Marjolein Diepeveen, Alexandra R M Brandt-Kerkhof, Esther van Meerten, Stijn L W Koolen, Ignace H J T de Hingh, Cornelis Verhoef, Ron H J Mathijssen & Jacobus W A Burger. (2023) Phase I study of intraperitoneal irinotecan combined with palliative systemic chemotherapy in patients with colorectal peritoneal metastases. British Journal of Surgery.
Crossref
Crossref
Yin Liu, Xi Zhang, Hui-Fang Xu, Ji-Hai Shi, Yu-Qian Zhao, Ling-Bin Du, Yun-Yong Liu, Wen-Jun Wang, He-Lu Cao, Li Ma, Juan-Xiu Huang, Ji Cao, Li Li, Yan-Ping Fan, Xiao-Fen Gu, Chang-Yan Feng, Qian Zhu, Xiao-Hui Wang, Jing-Chang Du, Jian-Gong Zhang, Shao-Kai Zhang & You-Lin Qiao. (2023) Real-World Utilization, Barriers, and Factors Associated With the Targeted Treatment of Metastatic Colorectal Cancer Patients in China: A Multi-Center, Hospital-Based Survey Study. International Journal of Public Health 68.
Crossref
Crossref
Cheng Huang, Jv Chen & Yongli Situ. (2023) Liver cirrhosis following oxaliplatin-based adjuvant chemotherapy for rectal cancer. Journal of Oncology Pharmacy Practice, pages 107815522311786.
Crossref
Crossref
Brian V. Monahan, Takshaka Patel & Juan Lucas Poggio. (2023) Stage IV Colorectal Cancer at Initial Presentation versus Progression during and after Treatment, Differences in Management: Management Differences for Initial Presentation versus Progression of Disease after Initial Treatment. Clinics in Colon and Rectal Surgery.
Crossref
Crossref
Oscar Hernandez Dominguez, Sumeyye Yilmaz & Scott R. Steele. (2023) Stage IV Colorectal Cancer Management and Treatment. Journal of Clinical Medicine 12:5, pages 2072.
Crossref
Crossref
Blake R Rushing, Anne E Thessen, Ghada A Soliman, Aramandla Ramesh & Susan C J Sumner. (2023) The exposome and nutritional pharmacology and toxicology: a new application for metabolomics. Exposome 3:1.
Crossref
Crossref
Lingyu Han, Weixing Dai, Wenqin Luo, Li Ye, Hongsheng Fang, Shaobo Mo, Qingguo Li, Ye Xu, Renjie Wang & Guoxiang Cai. (2023) Enhanced De Novo Lipid Synthesis Mediated by FASN Induces Chemoresistance in Colorectal Cancer. Cancers 15:3, pages 562.
Crossref
Crossref
Yue Liu, Qian Xiao, Jinjie He, Hanguang Hu, Jinlin Du, Yuping Zhu, Jiaqi Chen, Zhuo Liu, Jianping Wang, Lifeng Sun, Dong Xu, Jun Li, Xiujun Liao, Jianwei Wang, Yibo Cai, Cheng Cai, Zhekang Jin, Liuhong Wang, Ying Yuan & Kefeng Ding. (2022) Phase II study of anlotinib in combination with oxaliplatin and capecitabine for patients with RAS/BRAF wild-type metastatic colorectal adenocarcinoma as the first-line therapy. BMC Medicine 20:1.
Crossref
Crossref
Midhun Malla, Jacob Fuqua, Sarbajit Mukherjee & Richard M. Goldberg. (2022) Optimal First-Line Therapy for Metastatic Adenocarcinoma of the Esophagus. Current Treatment Options in Oncology 23:12, pages 1748-1760.
Crossref
Crossref
Shuzhen Liu, Kun Zhang & Xianfang Hu. (2022) Comparative efficacy and safety of Chinese medicine injections combined with capecitabine and oxaliplatin chemotherapies in treatment of colorectal cancer: A bayesian network meta-analysis. Frontiers in Pharmacology 13.
Crossref
Crossref
Xiang Lin, Li Xu, Huicheng Tan, Xinyi Zhang, Huan Shao, Li Yao & Xuan Huang. (2022) The potential effects and mechanisms of Gegen Qinlian Decoction in oxaliplatin-resistant colorectal cancer based on network pharmacology. Heliyon 8:11, pages e11305.
Crossref
Crossref
Qiang Sun, Kai Xu, Shifeng Teng, Wenqiang Wang, Wei Zhang, Xinxing Li & Zhiqian Hu. (2022) Construction of Nomogram-Based Prediction Model for Clinical Prognosis of Patients with Stage II and III Colon Cancer Who Underwent Xelox Chemotherapy after Laparoscopic Radical Resection. Journal of Oncology 2022, pages 1-8.
Crossref
Crossref
Shuhei Sakai, Shinji Kobuchi, Yukako Ito & Toshiyuki Sakaeda. (2022) Assessment of Drug–drug Interaction and Optimization in Capecitabine and Irinotecan Combination Regimen using a Physiologically Based Pharmacokinetic Model. Journal of Pharmaceutical Sciences 111:5, pages 1522-1530.
Crossref
Crossref
Houshan Yao, Huilin Xu, Shi Qiu, Jiani Chen, Zeshuai Lin, Jiawei Zhu, Xiaomeng Sun, Qianmin Gao, Xintao Chen, Chaowen Xi, Doudou Huang, Feng Zhang, Shouhong Gao, Zhipeng Wang, Jian Zhang, Xuan Liu, Guoliang Ren, Xia Tao, Mingming Li & Wansheng Chen. (2022) Choline deficiency-related multi-omics characteristics are susceptible factors for chemotherapy-induced thrombocytopenia. Pharmacological Research 178, pages 106155.
Crossref
Crossref
Maria G. Fencer, Catherine H. Davis & Kristen R. Spencer. (2022) Current Updates on HER2–Directed Therapies in Metastatic Colorectal Cancer. Current Colorectal Cancer Reports 18:2, pages 27-37.
Crossref
Crossref
Yue Zhou, Qing Zhang, Minjia Wang, Chengzhi Huang & Xueqing Yao. (2022) Effective Delivery of siRNA-Loaded Nanoparticles for Overcoming Oxaliplatin Resistance in Colorectal Cancer. Frontiers in Oncology 12.
Crossref
Crossref
Ruba Hamed, Sam Marks, Helen Mcelligott, Roshni Kalachand, Hawa Ibrahim, Said Atyani, Greg Korpanty & Nemer Osman. (2021)
Inoperable
de novo
metastatic colorectal cancer with primary tumour
in situ
: Evaluating discordant responses to upfront systemic therapy of the primary tumours and metastatic sites and complications arising from primary tumours (experiences from an Irish Cancer Centre)
. Molecular and Clinical Oncology 16:2.
Crossref
Crossref
Maeve A. Hennessy, Anna Linehan, Darren Cowzer, Zachary L. Coyne, Orla Fitzpatrick, Fiona Barrett, Roisin Ni Dhonaill, Bryan T. Hennessy, Liam Grogan, Patrick G. Morris & Oscar S. Breathnach. (2021) Chemotherapy in the Covid-19 era: the patient’s perception. Irish Journal of Medical Science (1971 -) 190:4, pages 1303-1308.
Crossref
Crossref
Katie Watts, Christopher Wills, Ayman Madi, Claire Palles, Timothy S. Maughan, Richard Kaplan, Nada A. Al‐Tassan, Rachel Kerr, David Kerr, Victoria Gray, Hannah West, Richard S. Houlston, Valentina Escott‐Price & Jeremy P. Cheadle. (2021) Genome‐wide association studies of toxicity to oxaliplatin and fluoropyrimidine chemotherapy with or without cetuximab in 1800 patients with advanced colorectal cancer. International Journal of Cancer 149:9, pages 1713-1722.
Crossref
Crossref
Yeelon Yeoh, Teck Yew Low, Nadiah Abu & Pey Yee Lee. (2021) Regulation of signal transduction pathways in colorectal cancer: implications for therapeutic resistance. PeerJ 9, pages e12338.
Crossref
Crossref
Nuttavut Sumransub, Kornpong Vantanasiri, Ajay Prakash & Emil Lou. (2021) Advances and new frontiers for immunotherapy in colorectal cancer: Setting the stage for neoadjuvant success?. Molecular Therapy - Oncolytics 22, pages 1-12.
Crossref
Crossref
Karynsa Kilpatrick, Jaime L. Shaw, Renee Jaramillo, Andrew Toler, Melissa Eisen, Laura Sangaré & Gerald A. Soff. (2021) Occurrence and Management of Thrombocytopenia in Metastatic Colorectal Cancer Patients Receiving Chemotherapy: Secondary Analysis of Data From Prospective Clinical Trials. Clinical Colorectal Cancer 20:2, pages 170-176.
Crossref
Crossref
Al B. BensonAlan P. VenookMahmoud M. Al-HawaryMustafa A. ArainYi-Jen ChenKristen K. CiomborStacey CohenHarry S. CooperDustin DemingLinda FarkasIgnacio Garrido-LagunaJean L. GremAndrew GunnJ. Randolph HechtSarah HoffeJoleen HubbardSteven HuntKimberly L. JohungNatalie KirilcukSmitha KrishnamurthiWells A. MessersmithJeffrey MeyerhardtEric D. MillerMary F. MulcahySteven NurkinMichael J. OvermanAparna ParikhHitendra PatelKatrina PedersenLeonard SaltzCharles SchneiderDavid ShibataJohn M. SkibberConstantinos T. SofocleousElena M. StoffelEden Stotsky-HimelfarbChristopher G. Willett, Kristina M. GregoryLisa A. Gurski. (2021) Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network 19:3, pages 329-359.
Crossref
Crossref
Marina Sáez‐Belló, Víctor Mangas‐Sanjuán, Mª. Amparo Martínez‐Gómez, Mª. Ángeles López‐Montenegro Soria, Mónica Climente‐Martí & Matilde Merino‐Sanjuán. (2020) Evaluation of ABC gene polymorphisms on the pharmacokinetics and pharmacodynamics of capecitabine in colorectal patients: Implications for dosing recommendations. British Journal of Clinical Pharmacology 87:3, pages 905-915.
Crossref
Crossref
Florian Moik, Alexander Makatsariya & Cihan Ay. (2021) Challenging anticoagulation cases: Cancer-associated venous thromboembolism and chemotherapy-induced thrombocytopenia – A case-based review of clinical management. Thrombosis Research 199, pages 38-42.
Crossref
Crossref
Shuhei Sakai, Shinji Kobuchi, Yukako Ito & Toshiyuki Sakaeda. (2021) A Physiologically Based Pharmacokinetic–Pharmacodynamic Model for Capecitabine in Colorectal Cancer Rats: Simulation of Antitumor Efficacy at Various Administration Schedules. European Journal of Drug Metabolism and Pharmacokinetics 46:2, pages 301-315.
Crossref
Crossref
Leah H. Biller & Deborah Schrag. (2021) Diagnosis and Treatment of Metastatic Colorectal Cancer. JAMA 325:7, pages 669.
Crossref
Crossref
Pilar García-Alfonso, Andrés Jesús Muñoz Martín, Laura Ortega Morán, Javier Soto Alsar, Gabriela Torres Pérez-Solero, Montserrat Blanco Codesido, Pilar Aitana Calvo Ferrandiz & Silvina Grasso Cicala. (2021) Oral drugs in the treatment of metastatic colorectal cancer. Therapeutic Advances in Medical Oncology 13, pages 175883592110090.
Crossref
Crossref
Kirollos S Hanna, Eve M Segal, Ashley Barlow & Brooke Barlow. (2020) Clinical strategies for optimizing infusion center care through a pandemic. Journal of Oncology Pharmacy Practice 27:1, pages 165-179.
Crossref
Crossref
Qiong Duan, Bin-Hui Chen & Yi Lin. (2020) Down-regulation of ClC-3 enhances chemosensitivity of colorectal cancer cells to oxaliplatin by inhibiting autophagy. World Chinese Journal of Digestology 28:24, pages 1235-1242.
Crossref
Crossref
Ashok Varma, Mathaiyan Jayanthi, Biswajit Dubashi, Deepak Gopal Shewade & Rajan Sundaram. (2020)
Genetic influence of
DPYD*9A
polymorphism on plasma levels of 5-fluorouracil and subsequent toxicity after oral administration of capecitabine in colorectal cancer patients of South Indian origin
. Drug Metabolism and Drug Interactions 35:4.
Crossref
Crossref
Reza Negarandeh, Ebrahim Salehifar, Fatemeh Saghafi, Hossein Jalali, Ghasem Janbabaei, Mohammad Javad Abdhaghighi & Anahita Nosrati. (2020) Evaluation of adverse effects of chemotherapy regimens of 5-fluoropyrimidines derivatives and their association with DPYD polymorphisms in colorectal cancer patients. BMC Cancer 20:1.
Crossref
Crossref
Ryo Ohta, Takeshi Yamada, Keisuke Hara, Takuma Iwai, Kohji Tanakaya, Keiichiro Ishibashi, Kazuhiko Yoshimatsu, Chihiro Kosugi, Masahiro Tsubaki, Hideo Nakajima, Masatoshi Oya, Hiroshi Yoshida, Keiji Koda & Hideyuki Ishida. (2020) Oxaliplatin-induced increase in splenic volume: experiences from multicenter study in Japan. International Journal of Clinical Oncology 25:12, pages 2075-2082.
Crossref
Crossref
Xubing Zhang, Qingbin Wu, Mingtian Wei, Xiangbing Deng, Chaoyang Gu & Ziqiang Wang. (2020) Oxaliplatin versus mitomycin C in HIPEC for peritoneal metastasis from colorectal cancer: a systematic review and meta-analysis of comparative studies. International Journal of Colorectal Disease 35:10, pages 1831-1839.
Crossref
Crossref
Majed Alshamrani, Atika AlHarbi, Nora Alkhudair, Fouad AlNajjar, Mansoor Khan, Abdulaziz Ben Obaid, Amr Khardaly, Eshtyag Bajnaid, Hadeel Samarkandi, Aeshah AlAzmi, Salman Alabdali & Mohammed AlNahedh. (2020) Practical strategies to manage cancer patients during the COVID-19 pandemic: Saudi Oncology Pharmacy Assembly Experts recommendations. Journal of Oncology Pharmacy Practice 26:6, pages 1429-1440.
Crossref
Crossref
Ashok Varma, Jayanthi Mathaiyan, Deepak Shewade, Biswajit Dubashi & Kodidela Sunitha. (2020)
Influence of
ABCB‐1, ERCC‐1
and
ERCC‐2
gene polymorphisms on response to capecitabine and oxaliplatin (CAPOX) treatment in colorectal cancer (CRC) patients of South India
. Journal of Clinical Pharmacy and Therapeutics 45:4, pages 617-627.
Crossref
Crossref
Qiuhua Lai, Qingyuan Li, Chengcheng He, Yuxin Fang, Simin Lin, Jianqun Cai, Jian Ding, Qian Zhong, Yue Zhang, Changjie Wu, Xinke Wang, Juan He, Yongfeng Liu, Qun Yan, Aimin Li & Side Liu. (2020) CTCF promotes colorectal cancer cell proliferation and chemotherapy resistance to 5-FU via the P53-Hedgehog axis. Aging 12:16, pages 16270-16293.
Crossref
Crossref
Federico Waisberg, Diego Enrico, Martín Angel & Matías Chacón. (2020) Cancer Treatment Adaptations in the COVID-19 Era. JCO Oncology Practice 16:6, pages 305-307.
Crossref
Crossref
Shuhei Sakai, Shinji Kobuchi, Yukako Ito & Toshiyuki Sakaeda. (2020) Assessment of pharmacokinetic variations of capecitabine after multiple administration in rats: a physiologically based pharmacokinetic model. Cancer Chemotherapy and Pharmacology 85:5, pages 869-880.
Crossref
Crossref
AshokV Kalidindi, Biswajit Dubashi, M Jayanthi & DG Shewade. (2020) Efficacy and safety of capecitabine and oxaliplatin (CAPOX) treatment in colorectal cancer: An observational study from a tertiary cancer center in South India. Indian Journal of Cancer 0:0, pages 0.
Crossref
Crossref
David A. Mahvi & David M. Mahvi. 2020. Abeloff's Clinical Oncology. Abeloff's Clinical Oncology
846
862.e4
.
Xiaojie Wang, Waleed M. Ghareeb, Yiyi Zhang, Qian Yu, Xingrong Lu, Ying Huang, Shenghui Huang, Yanwu Sun & Pan Chi. (2019) Hypermethylated and downregulated MEIS2 are involved in stemness properties and oxaliplatin‐based chemotherapy resistance of colorectal cancer. Journal of Cellular Physiology 234:10, pages 18180-18191.
Crossref
Crossref
Nobuki Ichikawa, Shigenori Homma, Tohru Funakoshi, Masahiro Hattori, Masanori Sato, You Kamiizumi, Kazuyoshi Omori, Masaru Nomura, Ryoichi Yokota, Masahiko Koike, Hirofumi Kon, Keisa Takeda, Hiroyuki Ishizu, Kunihiro Hirose, Daisuke Kuraya, Takahisa Ishikawa, Ryohei Murata, Hiroaki Iijima, Futoshi Kawamata, Tadashi Yoshida, Yosuke Ohno, Nozomi Minagawa, Norihiko Takahashi & Akinobu Taketomi. (2019) Preoperative FOLFOX in resectable locally advanced rectal cancer can be a safe and promising strategy: the R-NAC-01 study. Surgery Today 49:8, pages 712-720.
Crossref
Crossref
Christopher Lieu, Erin B. Kennedy, Emily Bergsland, Jordan Berlin, Thomas J. George, Sharlene Gill, Philip J. Gold, Alex Hantel, Lee Jones, Najjia Mahmoud, Jeffrey Meyerhardt, Arden M. Morris, Erika Ruíz-García, Y. Nancy You & Nancy Baxter. (2019) Duration of Oxaliplatin-Containing Adjuvant Therapy for Stage III Colon Cancer: ASCO Clinical Practice Guideline. Journal of Clinical Oncology, pages JCO.19.00281.
Crossref
Crossref
Yuanyuan Fu, Chengheng Liao, Kai Cui, Xiao Liu & Wentong Fang. (2019) Antitumor pharmacotherapy of colorectal cancer in kidney transplant recipients. Therapeutic Advances in Medical Oncology 11, pages 175883591987619.
Crossref
Crossref
Xinkui Liu, Jiarui Wu, Dan Zhang, Kaihuan Wang, Xiaojiao Duan & Xiaomeng Zhang. (2018)
A Network Pharmacology Approach to Uncover the Multiple Mechanisms of
Hedyotis diffusa
Willd. on Colorectal Cancer
. Evidence-Based Complementary and Alternative Medicine 2018, pages 1-12.
Crossref
Crossref
Naruhiko Ikoma, Kanwal Raghav & George Chang. (2017) An Update on Randomized Clinical Trials in Metastatic Colorectal Carcinoma. Surgical Oncology Clinics of North America 26:4, pages 667-687.
Crossref
Crossref
Lei Zhang, Ying Mu, Anqi Zhang, Jiaping Xie, Shuangfeng Chen, Fang Xu, Weihua Wang, Yingxin Zhang, Shaoda Ren & Changhui Zhou. (2017) Cytokine-induced killer cells/dendritic cells-cytokine induced killer cells immunotherapy combined with chemotherapy for treatment of colorectal cancer in China: a meta-analysis of 29 trials involving 2,610 patients. Oncotarget 8:28, pages 45164-45177.
Crossref
Crossref